IFM Therapeutics

Mar 13, 2024

Novartis Acquires IFM Due to Develop First-In-Class STING Antagonist Program Targeting Innate Immune System

Jan 07, 2020

IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer

Dec 02, 2019

IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer

Nov 20, 2019

New Research Demonstrates Second Direct Link Between Inflammasome Activation and Alzheimer's Disease

Sep 05, 2019

IFM Therapeutics Announces Collaboration and Exclusive Option Agreement for cGAS/STING-Focused Subsidiary, IFM Due

May 08, 2019

IFM Therapeutics and Novartis Complete Previously Announced Acquisition of IFM Tre

Apr 01, 2019

Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System

Jun 20, 2018

IFM Therapeutics, LLC Appoints World-Renowned Physicians and Researchers to Clinical Advisory Board

Mar 07, 2018

IFM Therapeutics and Bristol-Myers Squibb Awarded 2017 Deal of the Year by Clarivate Analytics

Jan 11, 2018

Western Diet Causes Long-Term Impact on Body's Immune System Even After Dietary Changes

Dec 20, 2017

New Research Demonstrates Direct Link between Inflammasome Activation and Amyloid-b Pathology in Alzheimer's Disease

Dec 20, 2017

IFM Therapeutics LLC Appoints Dr. Michael Heneka to Clinical Advisory Board

Oct 05, 2017

IFM Therapeutics LLC Appoints William R. Roush as Executive Vice President of Chemistry